302 related articles for article (PubMed ID: 26885070)
1. Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer.
Jiang J; Bo D; Chang X; Cheng H; Ye X; Cui H
Int J Clin Exp Med; 2015; 8(11):21303-10. PubMed ID: 26885070
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
3. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
4. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.
Drapkin R; von Horsten HH; Lin Y; Mok SC; Crum CP; Welch WR; Hecht JL
Cancer Res; 2005 Mar; 65(6):2162-9. PubMed ID: 15781627
[TBL] [Abstract][Full Text] [Related]
5. Human epididymis protein 4 immunostaining of malignant ascites differentiates cancer of Müllerian origin from gastrointestinal cancer.
Stiekema A; Van de Vijver KK; Boot H; Broeks A; Korse CM; van Driel WJ; Kenter GG; Lok CA
Cancer Cytopathol; 2017 Mar; 125(3):197-204. PubMed ID: 28199067
[TBL] [Abstract][Full Text] [Related]
6. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
7. Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors.
Blackman A; Mitchell J; Rowswell-Turner R; Singh R; Kim KK; Eklund E; Skates S; Bast RC; Messerlian G; Miller MC; Moore RG
Tumour Biol; 2021; 43(1):355-365. PubMed ID: 34957977
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of HE4 Tissue Expression in Serous Epithelial Ovarian Carcinoma.
Sethi A; Kumar L; Mathur S; Mahey R; Kachhawa G; Bhatla N
South Asian J Cancer; 2022 Apr; 11(2):125-132. PubMed ID: 36466984
[TBL] [Abstract][Full Text] [Related]
9. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
[TBL] [Abstract][Full Text] [Related]
10. Increased HE4 mRNA Expression Correlates with High Level Of eIF3a mRNA And Better Survival in Women with Epithelial Ovarian Cancer.
Luo CH; Zhao M; Tang YX; Shahabi S; Fang KN; Chen Y; Tang Y; Chen XY; Wang J; Zhou HH
J Cancer; 2018; 9(6):1088-1095. PubMed ID: 29581788
[TBL] [Abstract][Full Text] [Related]
11. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.
Zhu YF; He LS; Zhang ZD; Huang QS
Asian Pac J Trop Med; 2012 Dec; 5(12):925-30. PubMed ID: 23199707
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.
Paek J; Lee SH; Yim GW; Lee M; Kim YJ; Nam EJ; Kim SW; Kim YT
Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):338-42. PubMed ID: 21683503
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
15. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
[TBL] [Abstract][Full Text] [Related]
16. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer.
Manganaro L; Michienzi S; Vinci V; Falzarano R; Saldari M; Granato T; Viggiani V; Frati L; Anastasi E
Oncol Rep; 2013 Nov; 30(5):2481-7. PubMed ID: 23970060
[TBL] [Abstract][Full Text] [Related]
17. Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers.
Yanaranop M; Jantarateptewan N; Tiyayon J; Nakrangsee S
Int J Gynecol Cancer; 2018 Jul; 28(6):1058-1065. PubMed ID: 29975290
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.
Previs R; Leath CA; Coleman RL; Herzog TJ; Krivak TC; Brower SL; Tian C; Secord AA
Gynecol Oncol; 2015 Aug; 138(2):267-71. PubMed ID: 26037898
[TBL] [Abstract][Full Text] [Related]
19. [Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases].
Zhao Y; Wang Y; Shen Dh; Song Rn; Xu Q; Li Y; Cui H; Tang J; Wei Lh
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):123-8. PubMed ID: 21321635
[TBL] [Abstract][Full Text] [Related]
20. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
Geyer JT; López-García MA; Sánchez-Estevez C; Sarrió D; Moreno-Bueno G; Franceschetti I; Palacios J; Oliva E
Am J Surg Pathol; 2009 Aug; 33(8):1157-63. PubMed ID: 19542870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
